CLRBW News

Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026

Cellectar Biosciences Expands Global Intellectual Property Estate